These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37045991)

  • 1. Predictors of placebo response in three large clinical trials of the V1a receptor antagonist balovaptan in autism spectrum disorder.
    Tobe R; Zhu Y; Gleissl T; Rossomanno S; Veenstra-VanderWeele J; Smith J; Hollander E
    Neuropsychopharmacology; 2023 Jul; 48(8):1201-1216. PubMed ID: 37045991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial.
    Jacob S; Veenstra-VanderWeele J; Murphy D; McCracken J; Smith J; Sanders K; Meyenberg C; Wiese T; Deol-Bhullar G; Wandel C; Ashford E; Anagnostou E
    Lancet Psychiatry; 2022 Mar; 9(3):199-210. PubMed ID: 35151410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Balovaptan vs Placebo for Social Communication in Childhood Autism Spectrum Disorder: A Randomized Clinical Trial.
    Hollander E; Jacob S; Jou R; McNamara N; Sikich L; Tobe R; Smith J; Sanders K; Squassante L; Murtagh L; Gleissl T; Wandel C; Veenstra-VanderWeele J
    JAMA Psychiatry; 2022 Aug; 79(8):760-769. PubMed ID: 35793101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder.
    Bolognani F; Del Valle Rubido M; Squassante L; Wandel C; Derks M; Murtagh L; Sevigny J; Khwaja O; Umbricht D; Fontoura P
    Sci Transl Med; 2019 May; 11(491):. PubMed ID: 31043521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Large multicenter randomized trials in autism: key insights gained from the balovaptan clinical development program.
    Jacob S; Anagnostou E; Hollander E; Jou R; McNamara N; Sikich L; Tobe R; Murphy D; McCracken J; Ashford E; Chatham C; Clinch S; Smith J; Sanders K; Murtagh L; Noeldeke J; Veenstra-VanderWeele J
    Mol Autism; 2022 Jun; 13(1):25. PubMed ID: 35690870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trial.
    King BH; Dukes K; Donnelly CL; Sikich L; McCracken JT; Scahill L; Hollander E; Bregman JD; Anagnostou E; Robinson F; Sullivan L; Hirtz D
    JAMA Pediatr; 2013 Nov; 167(11):1045-52. PubMed ID: 24061784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): systematic review and meta-regression analysis.
    Siafis S; Çıray O; Schneider-Thoma J; Bighelli I; Krause M; Rodolico A; Ceraso A; Deste G; Huhn M; Fraguas D; Mavridis D; Charman T; Murphy DG; Parellada M; Arango C; Leucht S
    Mol Autism; 2020 Aug; 11(1):66. PubMed ID: 32847616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder.
    Schnider P; Bissantz C; Bruns A; Dolente C; Goetschi E; Jakob-Roetne R; Künnecke B; Mueggler T; Muster W; Parrott N; Pinard E; Ratni H; Risterucci C; Rogers-Evans M; von Kienlin M; Grundschober C
    J Med Chem; 2020 Feb; 63(4):1511-1525. PubMed ID: 31951127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of V
    Kimi S; Maiti R; Srinivasan A; Mishra BR; Hota D
    Int J Dev Neurosci; 2024 Feb; 84(1):3-13. PubMed ID: 37641183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Cândido RCF; Menezes de Padua CA; Golder S; Junqueira DR
    Cochrane Database Syst Rev; 2021 Jan; 1(1):CD013011. PubMed ID: 33460048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
    Nasser A; Hull JT; Chaturvedi SA; Liranso T; Odebo O; Kosheleff AR; Fry N; Cutler AJ; Rubin J; Schwabe S; Childress A
    CNS Drugs; 2022 Aug; 36(8):897-915. PubMed ID: 35896943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylphenidate for children and adolescents with autism spectrum disorder.
    Sturman N; Deckx L; van Driel ML
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011144. PubMed ID: 29159857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents With Autism Spectrum Disorders: Study Protocol for AIMS-2-TRIALS-CT1.
    Parellada M; San José Cáceres A; Palmer M; Delorme R; Jones EJH; Parr JR; Anagnostou E; Murphy DGM; Loth E; Wang PP; Charman T; Strydom A; Arango C
    Front Psychiatry; 2021; 12():701729. PubMed ID: 34504446
    [No Abstract]   [Full Text] [Related]  

  • 15. Cannabinoid treatment for autism: a proof-of-concept randomized trial.
    Aran A; Harel M; Cassuto H; Polyansky L; Schnapp A; Wattad N; Shmueli D; Golan D; Castellanos FX
    Mol Autism; 2021 Feb; 12(1):6. PubMed ID: 33536055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atomoxetine, Parent Training, and Their Combination in Children With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.
    Handen BL; Aman MG; Arnold LE; Hyman SL; Tumuluru RV; Lecavalier L; Corbett-Dick P; Pan X; Hollway JA; Buchan-Page KA; Silverman LB; Brown NV; Rice RR; Hellings J; Mruzek DW; McAuliffe-Bellin S; Hurt EA; Ryan MM; Levato L; Smith T
    J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):905-15. PubMed ID: 26506581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using a Patient-Centered Outcome Measure to Test Methylphenidate Versus Placebo in Children with Autism Spectrum Disorder.
    Scahill L; Bearss K; Sarhangian R; McDougle CJ; Arnold LE; Aman MG; McCracken JT; Tierney E; Gillespie S; Postorino V; Vitiello B
    J Child Adolesc Psychopharmacol; 2017 Mar; 27(2):125-131. PubMed ID: 27893955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a phase Ib study of SB-121, an investigational probiotic formulation, a randomized controlled trial in participants with autism spectrum disorder.
    Schmitt LM; Smith EG; Pedapati EV; Horn PS; Will M; Lamy M; Barber L; Trebley J; Meyer K; Heiman M; West KHJ; Hughes P; Ahuja S; Erickson CA
    Sci Rep; 2023 Mar; 13(1):5192. PubMed ID: 36997569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial.
    Anagnostou E; Aman MG; Handen BL; Sanders KB; Shui A; Hollway JA; Brian J; Arnold LE; Capano L; Hellings JA; Butter E; Mankad D; Tumuluru R; Kettel J; Newsom CR; Hadjiyannakis S; Peleg N; Odrobina D; McAuliffe-Bellin S; Zakroysky P; Marler S; Wagner A; Wong T; Macklin EA; Veenstra-VanderWeele J
    JAMA Psychiatry; 2016 Sep; 73(9):928-37. PubMed ID: 27556593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder.
    Scahill L; McCracken JT; King BH; Rockhill C; Shah B; Politte L; Sanders R; Minjarez M; Cowen J; Mullett J; Page C; Ward D; Deng Y; Loo S; Dziura J; McDougle CJ;
    Am J Psychiatry; 2015 Dec; 172(12):1197-206. PubMed ID: 26315981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.